Shots:
- The P-III NAVIGATOR study involves assessing Tezepelumab + SOC vs PBO + SOC in 1061 adults (18–80yrs.) & adolescents (12–17yrs.) with severe, uncontrolled asthma, who were receiving treatment with medium/high dose ICS + at least 1 additional controller medication with/ out OCS
- The trial met its 1EPs i.e. 56% reduction in AAER @52wks. in the overall population. The study also met 1EPs in the subgroup of patients with low levels of eosinophils i.e. 41% & 39% reduction with <300 & 150 cells/microlitre respectively
- Tezepelumab is mAb that inhibits the action of TSLP and has received US FDA’s BT designation in Sept’2018 for patients with severe asthma, without an eosinophilic phenotype
Click here to read full press release/ article | Ref: Amgen | Image: Convenient MD
The post AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR Trial for Severe Asthma first appeared on PharmaShots.
